BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34868996)

  • 1. Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology.
    Manne A; Woods E; Tsung A; Mittra A
    Front Oncol; 2021; 11():768009. PubMed ID: 34868996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
    Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
    Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in Biliary Tract Cancers: Where Are We?
    Kalyan A; Khosla H; Kim RD
    Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current options and future directions of systemic therapy for advanced biliary tract cancer.
    Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
    Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.
    Lo JH; Agarwal R; Goff LW; Heumann TR
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza.
    Queiroz MM; Lima NF; Biachi de Castria T
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.
    Iyer P; Chen MH; Goyal L; Denlinger CS
    Chin Clin Oncol; 2020 Feb; 9(1):7. PubMed ID: 32146818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
    Aimar G; Paratore C; Zichi C; Marino D; Sperti E; Caglio A; Gamba T; De Vita F; Di Maio M
    Explor Target Antitumor Ther; 2021; 2(5):448-464. PubMed ID: 36045702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Medicine in Biliary Tract Cancer.
    Scott AJ; Sharman R; Shroff RT
    J Clin Oncol; 2022 Aug; 40(24):2716-2734. PubMed ID: 35839428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
    Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
    J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel insights into molecular and immune subtypes of biliary tract cancers.
    Bramel ER; Sia D
    Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging molecular target antagonists for the treatment of biliary tract cancer.
    Lombardi P; Marino D; Fenocchio E; ChilĂ  G; Aglietta M; Leone F
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
    Grivas P; Yu EY
    Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.